ACURATE Neo TAVR Valve Fails to Demonstrate Non-Inferiority

In a randomized clinical trial, SCOPE II, a new self-expanding bioprosthetic valve used in transcatheter aortic valve replacement (TAVR) failed to demonstrate non-inferiority compared to an existing self-expanding valve.
 
Findings were reported today at TCT Connect, the 32nd annual scientific symposium of the Cardiovascular Research Foundation (CRF). TCT is the world’s premier educational meeting specializing in interventional cardiovascular medicine. The study was also published simultaneously in Circulation.
 
The SCOPE II trial was designed to compare the clinical outcomes of the ACURATE neo and CoreValve Evolut valves. A total of 796 patients aged 75 years or older with symptomatic severe aortic stenosis and an indication for transfemoral TAVR as agreed by the Heart Team were recruited at 23 tertiary heart valves centers in Denmark, France, Germany, Italy, Spain and the United Kingdom. Participants were randomly assigned (1:1) to receive treatment with the ACURATE neo (n=398) or the CoreValve Evolut devices (n=398).
 
The primary safety endpoint, powered for non-inferiority of the ACURATE neo valve using a noninferiority margin of 6 percent, was the composite of all-cause mortality or stroke at 12 months. The primary efficacy endpoint, powered for superiority, was new permanent pacemaker implantation at 30 days. Secondary endpoints included clinical efficacy and safety endpoints at 30 days and 12 months.
 
In the intention-to-treat analysis, death or stroke at one year was 15.8 percent in the ACURATE neo group compared to 13.9 percent in the CoreValve Evolut group, while in the per-protocol analysis it was 15.3 percent vs. 14.3 percent. Noninferiority of the ACURATE neo was not met for the primary endpoint in the intent-to-treat analysis, while it was met in the per-protocol analysis. Based on the prespecified statistical plan, due to these inconsistent results, non-inferiority was not established for the primary endpoint.
 
New pacemaker implantation at 30 days was 10.5 percent with ACURATE neo compared to 18.0 percent with CoreValve Evolut (Risk Difference -7.5 percent, 95 percent CI -12.4–-2.60, P= 0.0027). Cardiac death at 30 days (2.8 percent vs 0.8 percent, p=0.03) and one year (8.4 percent vs 3.9 percent, p=0.01) was greater in the ACURATE neo group. The rate of moderate-severe aortic regurgitation was 9.6 percent vs 2.9 percent (P<0.0001) at 30 days and 4.0 percent vs. 3.3 percent (P<0.0001) at one year.
 
“TAVR with the ACURATE neo valve did not meet noninferiority compared with the CoreValve Evolut bioprosthesis with respect to a composite of death or stroke at one year,” said Corrado Tamburino, MD, PhD, Division of Cardiology at C.A.S.T. (Centro Alte Specialità e Trapianti) Policlinico – University of Catania, Catania, Italy. “In a secondary analysis with limited statistical power, cardiac death was increased at one year in patients who received the ACURATE neo valve. The two valves also differed with respect to technical characteristics such as degree of aortic regurgitation and need for new permanent pacemaker implantation.”
 
The SCOPE II trial was sponsored by the Center for European Research Initiatives in Cardiovascular Medicine (CERIC). Prof. Tamburino reported the following disclosures: speaker fees from Medtronic.